AstraZeneca

Two linked cases of the new Omicron coronavirus variant have been detected in Britain connected to travel to southern Africa, health minister Sajid Javid said on Saturday

The third dose of AstraZeneca COVID vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer, according to a study in the UK

AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said

The drug was previously cleared by the US Food and Drug Administration in December for people with serious health problems or allergies who can't get adequate protection from vaccination

Evusheld was tested against the BA.1, BA.1.1, and BA.2 sub-variants of Omicron and it was also shown in the study to limit inflammation in the lungs - a critical symptom in severe Covid-19 infections

Many more vaccines are expected to be rejected as African nations and Covax said that from January they would not accept vaccines with less than two-and-a-half months' shelf life

The drug has been shown to reduce severe morbidity and mortality from Covid by 83 per cent

The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates

The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said

Our fight against COVID in the UK and around the world would not have been possible without the Oxford/AstraZeneca vaccine, said PM Boris Johnson

'If you look across Europe, with the rise in cases, there's also a corresponding lagged rise in deaths, but not in the UK,' says Dr Clive Dix, former chairman of the UK's Vaccine Task Force

Evusheld is one of only two antibody therapies authorised for use that showed neutralising activity against Omicron and against all other variants of concern in these two studies.

Vaxzevria significantly boosts antibodies against the rapidly spreading variant of the coronavirus, shows study

After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus's Delta variant after two doses

The study was done independently by investigators at the US Food and Drug Administration (USFDA), Center for Biologics Evaluation and Research.

The pledge builds on the collaboration between Oxford University, AstraZeneca and SII, the world's largest maker of vaccines

Two doses of Pfizer AstraZeneca Covid vaccines generate lower levels of antibodies against the Omicron variant of coronavirus.

The company said it has initiated engagements with Indian health authorities regarding its Covid prevention drug for people with weakened immune system

The US Food and Drug Administration (FDA) has granted emergency use authorisation to AstraZeneca's monoclonal antibody treatment for Covid-19 among people with weakened immune systems.

South Korean biopharmaceutical firm SK Bioscience's IPO raised $1.3 billion for the firm, which is a local Covid-19 vaccine-production partner with AstraZeneca Plc.